Amid continued failures in clinical trials of new drugs for Alzheimer’s disease (AD), researchers are beginning to have doubts about whether the "one drug, one target" paradigm is the way to go.
Biogen Inc./Eisai Co. Ltd.'s BACE inhibitor elenbecestat has just become the latest late-stage failure in the field, after showing an unfavorable risk-benefit ratio